Engineered immune cells take aim at Hard-to-Treat cancers
NCT ID NCT03745326
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 25 times
Summary
This study tested a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize a specific cancer mutation (KRAS G12D), and then given back to attack tumors. It involved 5 adults with advanced gastrointestinal, pancreatic, gastric, colon, or rectal cancers. Participants received chemotherapy before the cell infusion and took antibiotics for at least 6 months. The goal was to check safety and see if tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.